Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 399 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neuroinflammatory Disorders Clear all
Completed Phase 2 Interventional Results available

Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments

NCT03844412
View directory record Official record
Conditions
Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome, Irritable Bowel Syndrome, Migraines, Tension Headache, Endometriosis, Interstitial Cystitis, Back Pain, Chronic Fatigue Syndrome
Interventions
5% lidocaine/5 mg/ml 0.02% estradiol compound cream, Nortriptyline, Placebo cream, Placebo pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 17, 2026, 1:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

NCT00862277
View directory record Official record
Conditions
Meningococcal Infections, Meningitis
Interventions
Menactra®, Menomune®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
14 Years to 27 Years
Enrollment
763 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
20
States / cities
Little Rock, Arkansas • Fountain Valley, California • Marietta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 17, 2026, 1:44 AM EDT
Completed Not applicable Interventional Results available

Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health

NCT02669212
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
Cardiopulmonary Exercise Test (CPET)
Behavioral
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 60 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 17, 2026, 1:44 AM EDT
Not yet recruiting Phase 1 Interventional

[11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction

NCT07856043
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild, Neuroinflammation, Vascular Contributions to Cognitive Impairment and Dementia (VCID)
Interventions
[11C]PS13: [carbon-11]PS13; COX-1 PET radioligand, Sacubitril-Valsartan
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
50 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 1:44 AM EDT
Recruiting Not applicable Interventional

Controlled Trial of Hydrogen Water as a Treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT07753122
View directory record Official record
Conditions
Chronic Fatigue Syndrome (CFS)
Interventions
Placebo condition, Molecular hydrogen produced by a metallic magnesium tablet, consumed 3x a day dissolved in water. Treatment duration is 16 weeks.
Dietary Supplement
Lead sponsor
Fred Friedberg
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 17, 2026, 1:44 AM EDT
Completed Phase 2 Interventional

Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease

NCT00069316
View directory record Official record
Conditions
West Nile Virus
Interventions
Omr-IgG-am
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 1:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

NCT02752906
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
15 Years and older
Enrollment
810 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
29
States / cities
Birmingham, Alabama • Dothan, Alabama • Mesa, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 17, 2026, 1:44 AM EDT
Recruiting Phase 1 Interventional

Vancomycin Study in Multiple Sclerosis (MS)

NCT05539729
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Vancomycin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 1:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exploring the Biological Basis of Chronic Fatigue Syndrome

NCT04859257
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
Not listed
Lead sponsor
DxTerity Diagnostics
Industry
Eligibility
18 Years to 100 Years
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Compton, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 17, 2026, 1:44 AM EDT
Withdrawn No phase listed Observational

Therapy for Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder

NCT01872351
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
Nutraceuticals
Drug
Lead sponsor
Columbia University
Other
Eligibility
20 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 17, 2026, 1:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination

NCT01239043
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide, Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi
Industry
Eligibility
56 Years and older
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
6
States / cities
Scottsdale, Arizona • Bardstown, Kentucky • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 17, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of West Nile Virus Vaccine

NCT00300417
View directory record Official record
Conditions
West Nile Fever
Interventions
VRC-WNVDNA020-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 1:44 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand

NCT03958630
View directory record Official record
Conditions
Dementia
Interventions
11C-ER176, 11C-PIB, Positron Emission Tomography (PET) Scan
Drug · Diagnostic Test
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 17, 2026, 1:44 AM EDT
Active, not recruiting Phase 1 Interventional

Imaging of Neuro-Inflammation and the Risk for Post-Traumatic Epilepsy

NCT03999164
View directory record Official record
Conditions
Epilepsy, Post-Traumatic
Interventions
[18F]DPA-714 Positron Emission Tomography Scan
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 17, 2026, 1:44 AM EDT
Active, not recruiting Not applicable Interventional

Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center?

NCT05167227
View directory record Official record
Conditions
SARS-CoV-2 Acute Respiratory Disease, Myalgic Encephalomyelitis, Chronic Fatigue Syndrome, Post-acute Sequelae of SARS-COV-2 Infection, Post COVID-19 Condition
Interventions
Extension for Community Healthcare Outcomes
Other
Lead sponsor
Family Health Centers of San Diego
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 17, 2026, 1:44 AM EDT
Completed Not applicable Interventional

A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis

NCT00002305
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Flucytosine, Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 1:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

NCT01732627
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections, Invasive Meningococcal Disease
Interventions
Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
56 Years and older
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
12
States / cities
Chandler, Arizona • Scottsdale, Arizona • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 17, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28

NCT00526916
View directory record Official record
Conditions
Neurocysticercosis, Healthy
Interventions
[C-11]PBR28
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 17, 2026, 1:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

NCT03077438
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
2 Years to 9 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
35
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 17, 2026, 1:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Physiology in Polio Survivors

NCT00080600
View directory record Official record
Conditions
Postpoliomyelitis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
21 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vaccine to Prevent West Nile Virus Disease

NCT00106769
View directory record Official record
Conditions
Healthy, West Nile Fever, Healthy Volunteer, HV
Interventions
VRC-WNVDNA017-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 1:44 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Fungal Infection Susceptibility

NCT00001352
View directory record Official record
Conditions
Cryptococcal Infection, Cryptococcal Pneumonia, Pulmonary Cryptococcosis, Cryptococcal Meningitis, Cryptococcosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1993
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 1:44 AM EDT
Completed Phase 2 Interventional

Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)

NCT00001785
View directory record Official record
Conditions
HTLV-I Infection, Spinal Cord Disease, Tropical Spastic Paraparesis
Interventions
Recombinant human interferon beta-1a
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 1:44 AM EDT
Completed Phase 2 Interventional

Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis

NCT00000794
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Sulfadiazine, Clarithromycin, Atovaquone, Pyrimethamine, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
16
States / cities
Los Angeles, California • Miami, Florida • Honolulu, Hawaii + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 17, 2026, 1:44 AM EDT